CAGW Sends "Pharmaceutical Price Controls are Bad Medicine" to Congress
Letters to Officials
November 19, 2021
U.S. House/U.S. Senate
Washington, D.C. 20515/20510
Dear Representative/Senator,
On behalf of the more than one million members and supporters of Citizens Against Government Waste (CAGW), I am pleased to provide you with our latest issue brief, Pharmaceutical Price Controls are Bad for Medicine.
If Congress passes H.R. 5376, the $1.75 trillion Build Back Better (BBB) Act, the total amount of spending approved by Congress since the beginning of the COVID-19 pandemic will exceed $8.6 trillion. Among the worst provisions of the BBB Act to ostensibly pay for part of this monstrosity is to include price controls on drugs, like reference pricing, price caps, and rebates that are taken directly from H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act. The drug price control provisions will threaten medical innovation, reduce research and development, and cost American jobs, along with moving the country closer to a government-run healthcare system like Medicare for All.
If you have any questions about this report, please contact Eric Maus at emaus@cagw.org.
Sincerely,
Tom Schatz
President, CAGW
